Breaking News


Efficacy and safety of adalimumab in plaque psoriasis patients suboptimally treated with etanercept


A Canadian, multicenter, open-label study evaluated the safety and efficacy of adalimumab in 85 patients (aged 18-80 years) with plaque psoriasis who had failed to show or lost a satisfactory response to etanercept. Patients were randomized to two groups, A (n = 50) and B (n = 35). Group A included patients who had failed to respond to etanercept with a Physician's Global Assessment (PGA) score of 0 or 1 after 12 weeks of therapy. Group B patients had lost their PGA score of 0 or 1 at any time after their etanercept dose was decreased from 50 mg twice weekly to 50 mg/week. Patients received adalimumab 40 mg ...

to Continue Reading, Login Now

Please Login

If you are a registered user but you have forgotten your password, please click here
If you are not a registered user, please register here

return to breaking news list